Who makes GSP 301 Placebo NS pH 3.7?

GSP 301 Placebo NS pH 3.7 is developed by Glenmark Specialty S.A..

What development phase is GSP 301 Placebo NS pH 3.7 in?

GSP 301 Placebo NS pH 3.7 is in Phase 3.

Last reviewed 2026-04-23 · How we verify

GSP 301 Placebo NS pH 3.7

Glenmark Specialty S.A. · Phase 3 active Small molecule

This is a placebo formulation with no active pharmaceutical ingredient.

At a glance

Generic name	GSP 301 Placebo NS pH 3.7
Sponsor	Glenmark Specialty S.A.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

GSP 301 Placebo NS pH 3.7 is a control arm formulation used in clinical trials, containing no active drug substance. It is formulated as a neutral saline solution at pH 3.7 and serves as a comparator to assess the efficacy and safety of the active investigational drug in Phase 3 trials.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSP 301 Placebo NS pH 3.7 CI brief — competitive landscape report
GSP 301 Placebo NS pH 3.7 updates RSS · CI watch RSS
Glenmark Specialty S.A. portfolio CI